info@oncologystrategies.com   |   Overland Park, KS 66223

  • Facebook Basic Black
  • Twitter Basic Black
  • Black Instagram Icon

New report provides update on the fast moving, ever growing field of study in immuno-oncology. Full report in September Cancer Reviews Nature Discovery, Yu et al. 

Click on Charts to go to Article in Nature Reviews:

"The number of active drugs in development has gro...

"The Cancer Atlas, 3rd edition, a comprehensive global overview of cancer around the globe, concludes that progress in the fight against cancer is not only possible, but achievable. The report was produced by the American Cancer Society (ACS), the Union for Internation...

As we begin Breast Cancer Awareness Month, I am reminded of all the incredible colleagues, researchers, advocates, patients, family and friends that I have had the privilege of working with to fight this relentless disease. I send my regards and honor each of you!  

In the 1980s, only 4% of new drugs approved by the FDA were cancer treatments. But since 2010, cancer drugs have claimed 27% of new approvals—a share that doubled over the previous decade—according to a new report from the Tufts Center for the Study of Drug Development...

This seems like a silly question. Of course it is not enough. But physicians today feel the pressure to see more and more  patients, faster and faster due to increasing financial pressures. Fred N. Pelzman, MD has a very interesting perspective on this issue I wanted t...

PhRMA released its Cancer Medicines Value in Context slide deck. It is a rich cache of data and slides resources on the current cancer market. 

Click on image to download full deck of slide resources. 

The key take aways from the deck:

  • We have made remarkable progress...

"Check out the list below, and you'll notice several major blockbusters benefiting from biosimilar delays. You'll also see some small-molecule meds that are about to fall hard to generic competition. Overall, the assortment of drugs spans specialty fields such as cance...

See summary below and click on image to see full IQVIA 2019 report.

"There were 15 therapeutic oncology new active substances (NASs) and one supportive care NAS launched in the United States in 2018. Predictive biomarkers were associated with60% of therapeutic oncology...

"A record number of new oncology drugs has been approved in recent years, bringing new treatment options to patients. However, despite robust levels of pipeline activity, oncology remains a challenging area for research and development. This report examines the product...

Patient diagnosed with an aggressive form of brain cancer became the first person in the US to access an experimental treatment under the Right to Try law of 2017. 

Right-to-try laws are U.S. state and Federal laws that were created to let terminally ill patients try ex...

Please reload

Recent Posts
Please reload

Follow Us
  • Facebook Basic Square
  • Twitter Basic Square